Wire · operational-macro
Edwards Wins FDA Approval for PASCAL Tricuspid Valve Repair
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Edwards Lifesciences has received FDA approval for the PASCAL Precision system to treat severe tricuspid regurgitation in patients with intermediate or greater surgical risk, expanding beyond mitral valve repair. The approval also includes the PASCAL Ace with Capture Clarity system for enhanced mitral valve leaflet grasping confirmation.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 21 Oct 2026 and 22 Oct 2026.
◆ ◆ The Wire takeaway
You can now target a wider patient group with transcatheter valve repairs in the US as Edwards' dual approvals open more market access. Start lining up clinicians who need less invasive options for managing severe tricuspid and mitral regurgitation.
◆ Coverage
3 sources · first reported 21 Oct 2026 · latest 22 Oct 2026
◆ Related on Wire
◆ Topics